Zheng Quan Ri Bao Wang·2025-12-07 12:33Core Viewpoint - Haichuang Pharmaceutical's self-developed drug, Deuteroenzalutamide soft capsule, has been included in the national medical insurance drug list, effective from January 1, 2026, marking a significant milestone for the company and the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1][2] Group 1 - Deuteroenzalutamide soft capsule is a first-class new drug developed by Haichuang Pharmaceutical, specifically for treating mCRPC, and is recognized as a second-generation androgen receptor inhibitor [1] - The drug is the first domestically approved innovative medication for adult patients with mCRPC who have progressed after treatment with abiraterone acetate and chemotherapy, and have not previously received new androgen receptor inhibitors [1] - The drug demonstrates superior safety compared to other new endocrine therapies, significantly reducing the incidence of central nervous system adverse events and avoiding rash-related side effects, while also lowering the risk of common complications in elderly patients [1] Group 2 - The inclusion of Deuteroenzalutamide soft capsule in the national medical insurance drug list reflects the recognition of its clinical value, patient benefits, and innovation by the National Healthcare Security Administration [2] - This inclusion is expected to facilitate market promotion of the drug, reduce the financial burden on patients, and enhance drug accessibility [2] - Haichuang Pharmaceutical plans to actively support the implementation of medical insurance policies and continue to promote hospital access and core market coverage to meet patient medication needs more broadly [2]